ABN AMRO Bank N.V. Sells 134,842 Shares of Boston Scientific Corporation $BSX

ABN AMRO Bank N.V. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 23.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 438,340 shares of the medical equipment provider’s stock after selling 134,842 shares during the quarter. ABN AMRO Bank N.V.’s holdings in Boston Scientific were worth $27,731,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Renaissance Group LLC purchased a new stake in Boston Scientific during the 4th quarter valued at about $28,064,000. Rathbones Group PLC increased its stake in Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after purchasing an additional 477,680 shares during the period. Tounjian Advisory Partners LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $1,477,000. Waycross Partners LLC bought a new stake in Boston Scientific in the fourth quarter valued at approximately $2,384,000. Finally, Kepler Cheuvreux Suisse SA bought a new stake in Boston Scientific in the third quarter valued at approximately $26,955,000. 89.07% of the stock is owned by institutional investors.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 9,800 shares of company stock worth $554,012 over the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.1%

Boston Scientific stock opened at $44.16 on Friday. Boston Scientific Corporation has a one year low of $43.89 and a one year high of $109.50. The business’s fifty day moving average is $52.87 and its 200 day moving average is $71.13. The stock has a market capitalization of $65.64 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BSX shares. Mizuho cut their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Jefferies Financial Group cut their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, BTIG Research restated a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.